BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 24093615)

  • 21. Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma.
    Viganò M; Bhoori S; Lampertico P; Donato MF; Iavarone M; Grossi G; Facciorusso A; Caccamo L; Rossi G; Colombo M; Mazzaferro V
    Liver Int; 2015 Sep; 35(9):2187-93. PubMed ID: 25809541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
    Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
    Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients.
    Chen G; Liu H; Hu ZQ; Bai JH; Liu QY; Zhao YP; Gan XM; Wang F; Wang DD; Ma LJ; Li L
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):901-6. PubMed ID: 26011237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.
    Manini MA; Whitehouse G; Bruce M; Passerini M; Lim TY; Carey I; Considine A; Lampertico P; Suddle A; Heaton N; Heneghan M; Agarwal K
    Dig Liver Dis; 2018 Sep; 50(9):944-953. PubMed ID: 29735294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
    Yuefeng M; Weili F; Wenxiang T; Ligang X; Guiling L; Hongwei G; Wencai L; Xiaoguang W; Wei M; Zhongyi F
    Clin Transplant; 2011; 25(4):517-22. PubMed ID: 20560989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
    Darweesh SK; Gad AA; Akroof K; ElLatif ZA
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):607-612. PubMed ID: 30724767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
    Idilman R; Akyildiz M; Keskin O; Gungor G; Yilmaz TU; Kalkan C; Dayangac M; Cinar K; Balci D; Hazinedaroglu S; Tokat Y
    Clin Transplant; 2016 Oct; 30(10):1216-1221. PubMed ID: 27409074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin.
    Roche B; Roque-Afonso AM; Nevens F; Samuel D
    Transplantation; 2015 Jul; 99(7):1321-34. PubMed ID: 26038873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
    Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
    Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
    Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study.
    Liu Y; Ho WI; Deng F; Peng S; Lau WY; Chen H
    Transplant Proc; 2021 Jun; 53(5):1700-1706. PubMed ID: 34030872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of hepatitis B virus reinfection in liver transplant recipients.
    Roche B; Samuel D
    Intervirology; 2014; 57(3-4):196-201. PubMed ID: 25034488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of hepatitis B recurrence after liver transplantation using lamivudine and hepatitis B immune globulin.
    Ołdakowska-Jedynak U; Paczek L; Foroncewicz B; Mucha K; Nyckowski P; Zieniewicz K; Ziarkiewicz-Wróblewska B; Ziółkowski J; Pilecki T; Patkowski W; Górnicka B; Paczkowska A; Krawczyk M
    Ann Transplant; 2007; 12(3):28-32. PubMed ID: 18290567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B prophylaxis using lamivudine and individualized low-dose hepatitis B immunoglobulin in living donor liver transplantation.
    Jiang L; Yan L; Wen T; Li B; Zhao J; Yang J; Xu M; Wang W
    Transplant Proc; 2013; 45(6):2326-30. PubMed ID: 23953544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience.
    Yuan CH; Xiu DR; Jiang B; Li ZF; Li L; Song SB; Zhang TL
    Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):149-53. PubMed ID: 23558068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on.
    Hwang S; Ahn CS; Song GW; Kim KH; Moon DB; Oh HB; Lim YS; Lee HC; Ha TY; Jung DH; Chung YH; Lee SG
    Liver Transpl; 2011 Apr; 17(4):456-65. PubMed ID: 21445929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens.
    Anderson RD; Chinnakotla S; Guo L; Perrillo RP; Klintmalm GB; Davis GL
    Clin Transplant; 2007; 21(4):510-7. PubMed ID: 17645711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection.
    Perrakis A; Förtsch T; Del Medico A; Croner RS; Vassos N; Yedibela S; Lohmüller C; Zopf S; Hohenberger W; Müller V
    Transplant Proc; 2013 Jun; 45(5):1953-6. PubMed ID: 23769081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.